Adial Pharmaceuticals Inc (ADIL) — Cash Flow-to-Debt Ratio
Adial Pharmaceuticals Inc (ADIL) has a Cash Flow-to-Debt Ratio of -1.07x as of March 2026, meaning its operating cash flow of $-1.61 Million could theoretically repay -1% of its total liabilities ($1.51 Million) in one year. See Adial Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Adial Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Adial Pharmaceuticals Inc across 11 annual periods. Also explore Adial Pharmaceuticals Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Adial Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for Adial Pharmaceuticals Inc. For market capitalisation and broader financial context, see ADIL market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.65x | $-6.49 Million | $1.40 Million | ▲ +34.5% |
| 2024 | -7.09x | $-6.92 Million | $975.86K | ▲ +31.9% |
| 2023 | -10.42x | $-6.81 Million | $653.51K | ▼ -128.7% |
| 2022 | -4.55x | $-11.19 Million | $2.46 Million | ▼ -57.2% |
| 2021 | -2.90x | $-11.95 Million | $4.13 Million | ▲ +42.9% |
| 2020 | -5.07x | $-7.63 Million | $1.51 Million | ▲ +56.9% |
| 2019 | -11.76x | $-6.34 Million | $539.05K | ▼ -21.4% |
| 2018 | -9.68x | $-2.50 Million | $257.97K | ▼ -1919.9% |
| 2017 | -0.48x | $-494.86K | $1.03 Million | ▲ +55.4% |
| 2016 | -1.08x | $-274.38K | $255.02K | ▲ +87.7% |
| 2015 | -8.76x | $-465.22K | $53.08K | — |